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This study reports the development and characterization of taste masked, freeze-dried 9 
composite wafers for potential oral and buccal delivery of low dose aspirin (acetylsalicylic 10 
acid) to prevent thrombosis in elderly patients with dysphagia. The wafers were formulated 11 
by combining metolose (MET) with carrageenan (CAR), MET with chitosan (CS) at low 12 
molecular weight or CAR with CS using 45 % v/v ethanol as solvent for complete 13 
solubilization of acetylsalicylic acid. Each wafer contained 75 mg of acetylsalicylic acid and 14 
sweetener (sucralose, stevia or aspartame) with a drug: sweetener ratio of 1:1 w/w. The 15 
formulations were characterized for physical properties using texture analyzer (hardness and 16 
mucoadhesion), scanning electron microscopy (SEM), X-ray diffractometry (XRD), Fourier 17 
transform infrared (FTIR) spectroscopy, swelling capacity, and in vitro drug dissolution. 18 
Further, permeation studies with three different models (PermeapadTM artificial barrier, 19 
EpiOralTM and porcine buccal mucosa) using HPLC, cell viability using MTT assay and in 20 
vivo taste masking evaluation using human volunteers were undertaken. The sweeteners 21 
increased the hardness and adhesion of the wafers, XRD showed the crystalline nature of the 22 
samples attributed to acetylsalicylic acid, SEM confirmed a compacted polymer matrix due to 23 
recrystallized acetylsalicylic acid and sweeteners dispersed over the surface. Drug dissolution 24 
studies showed that acetylsalicylic acid was rapidly released in the first 20 minutes and then 25 
continuously over 1 hour. EpiOralTM had a higher cumulative permeation than porcine buccal 26 
tissue and PermeapadTM artificial barrier, while MTT assay using Vero cells (ATCC® CCL-27 
81) showed that the acetylsalicylic acid loaded formulations were non-toxic. In vivo taste 28 
masking study showed the ability of sucralose and aspartame to mask the bitter taste of 29 
acetylsalicylic acid and confirm that acetylsalicylic acid loaded MET:CAR, CAR:CS and 30 
MET:CS composite wafers containing sucralose or aspartame have potential for buccal 31 
delivery of acetylsalicylic acid in geriatric patients with dysphagia.  32 
 33 
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1. Introduction  37 
The buccal region of the oral mucosa cavity offers an attractive route of 38 
administration for systemic drug delivery. The oral cavity is highly acceptable by patient as 39 
the mucosa is relatively permeable with a rich blood supply, it is robust and shows short 40 
recovery times after stress or damage (Rathabone & Hadgraft , 1991). In addition, the oral 41 
mucosa route bypasses first pass metabolism by delivering the drug directly into the 42 
bloodstream. These factors make the oral mucosa a very attractive and feasible site for 43 
systemic drug delivery (Shojaei, 1998). Further, there has been an increased interest in novel 44 
drug delivery systems, over the past few decades, to improve safety, efficacy and patient 45 
compliance and increase the product patent life cycle (Panda, et al., 2012). Fast dissolving 46 
and sustained release lyophilized wafers and films are examples of formulations for oral and 47 
buccal mucosa drug delivery and can be used for various classes of drugs (Peh & Wong , 48 
1999).  49 
Acetylsalicylic acid (commonly referred to as aspirin) has anti-thrombin action, which 50 
inhibits clot formation, thus reducing the rate of heart attacks and strokes. Such 51 
administration for the purpose of reducing the clotting action of platelets, is referred to as 52 
‘low-dose aspirin’ (usually administered as a single tablet with 75mg of the drug). 53 
Acetylsalicylic acid acts as an acetylating agent and causes an irreversible inhibition of 54 
cyclooxygenase (COX)-1 which is an essential enzyme for the production of thromboxane A2 55 
(TxA2) in the platelets and supresses the generation of prostaglandin H2, which is a precursor 56 
of TxA2. TxA2 is a powerful stimulant of platelet aggregation and use of acetylsalicylic acid 57 
inactivates these platelets (Hovens, et al., 2006). Advantages of acetylsalicylic acid over other 58 
‘blood thinners’ such as warfarin, include low cost, once-daily administration and no need for 59 
dose monitoring (Mekaj, et al., 2015).  60 
Low dose acetylsalicylic acid is recommended for people with heart or vascular 61 
disease and patients who have had heart bypass surgery (British Medical Association, 2014) 62 
and most people who suffer from these problems are older (geriatric) patients, who usually 63 
also present with other chronic conditions. The impact of demographic ageing is likely to be 64 
of major significance in the coming decades, due to low birth rates and higher life 65 
expectancy. Older people generally require more prescribed medicines due to the presence of 66 
multiple conditions such as dysphagia (difficulty in swallowing). This occurs when the 67 
swallowing physiology changes with advancing age due to reduction in the muscle mass and 68 
connective tissue elasticity, resulting in the loss of strength and motion. These changes 69 
4 
 
reduce the effective and efficient flow of materials, such as food and medications through the 70 
upper aero digestive tract (Sura, et al., 2012). 71 
  Freeze-dried wafers are usually prepared by freeze-drying a polymeric solution or gel 72 
in an appropriate solvent (usually water). Freeze drying of water-soluble polymers produces 73 
shaped materials of highly porous nature that can be turned back to gels and solutions when 74 
they come into contact with fluids such as saliva. Lyophilized wafers can easily be applied to 75 
mucosa surfaces and they offer advantages over solid polymer gels and solvent cast films 76 
(Boateng, et al., 2010). Semi solid polymer gels flow easily after application, while wafers 77 
can maintain their swollen gel structure for a longer period and therefore longer residence 78 
times (Matthews, et al., 2005) to allow for effective drug absorption.  79 
 Freeze dried wafers are preferred over chewable acetylsalicylic acid tablets because 80 
the latter contains sorbitol which causes diarrhoea and flatulence. In addition the flavouring 81 
agents present in chewable tablets may cause ulcers in the oral cavity and the prolonged 82 
chewing may cause pain in the facial muscles which may increase the risk of poor adherence, 83 
medication errors or reduced patient quality of life. This is because of a loss of muscle 84 
strength in the mouth and throat regions, which makes it difficult for geriatric patients to 85 
chew. Further, these chewable tablets also show fragile (poor mechanical strength) and 86 
effervescent granular characteristics and therefore careful handling is required (Renu, et al., 87 
2015; (Farias & Boateng., 2018)). 88 
 This paper reports the formulation design and development of composite polymer 89 
based lyophilized wafers, taste masked with sweeteners, for potential buccal delivery of 90 
acetylsalicylic acid to geriatric patients and improved compliance from masking the bitter 91 
taste of the drug. The formulations were initially characterized for their physico-chemical 92 
properties (resistance to compression – ‘hardness’ and mucoadhesion), crystallinity, internal 93 
and surface morphology and chemical interactions. Drug dissolution and permeation studies 94 
using three different models (EpiOralTM, porcine buccal tissue and PermeapadTM an artificial 95 
buccal membrane) were performed for the optimized acetylsalicylic acid loaded and taste 96 
masked wafers using HPLC and finally the in vivo taste masking of acetylsalicylic acid by 97 
sucralose and aspartame was investigated using healthy adult human volunteers. 98 
  99 
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2. Materials and methods 100 
2.1 Materials  101 
Metolose (MET) grade type (60SH), viscosity (4000 cP) and MW (1261.4 g/mol) was 102 
obtained as a gift from Shin Etsu (Stevenage, Hertfordshire, UK), gelatin from porcine skin, 103 
MW (10000 g/mol), mucin from bovine submaxillary glands, MW (4000 kDa), MTT [3-(4,5-104 
dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide] reagent, dimethyl sulfoxide (DMSO) 105 
and acetyl salicylic acid were purchased from Sigma-Aldrich (Gillingham, UK). Κappa 106 
carrageenan [(CAR) (low viscosity grade NF 911, MW < 100,000Da, 25% sulfate esters, 107 
stable at pH values > 3.8)] was obtained as a gift from IMCD Ltd (Sutton, UK), low 108 
molecular weight chitosan (CS) with 95% degree of deacetylation and MW of 3000Da was 109 
purchased from Qingdao Yuda Century Economy and Trade CO, Ltd (China), calcium 110 
chloride, sodium chloride, sodium phosphate dibasic, magnesium chloride hexahydrate, 111 
potassium carbonate hemihydrate and sodium phosphate monobasic monohydrate were 112 
purchased from Fisher Scientific (Loughborough, UK). Sucralose, stevia and aspartame were 113 
obtained from a local ASDA Supermarket (London, UK). Dulbecco’s modified Eagle’s 114 
medium (DMEM), fetal bovine serum (FBS), penicillin, streptomycin and glutamine were all 115 
obtained from Gibco (Paisley, UK). Pig cheeks were obtained from a local slaughterhouse 116 
(Tunbridge Wells, Kent, UK). PermeapadTM was a gift from InnoME GmbH (Espelkamp, 117 
Germany) and EpiOralTM ORL-200 buccal tissue kit was purchased from MatTek 118 
Corporation (Ashland MA, USA). 119 
  120 
2.2 Formulation optimization  121 
  The drug loaded (DL) wafers were prepared by freeze-drying solutions combining 122 
MET with CAR and MET with CS in different weight ratios with each final wafer containing 123 
75 mg of acetylsalicylic acid as previously reported (Farias & Boateng, 2018) and 124 
subsequently taste masked using different ratios of sucralose (Suc), aspartame (Asp) and 125 
stevia (Stev) as summarized in (Table 1). Then 1 g was poured into each well of a 24 multi-126 
well plate (diameter 15.5 mm) with 75 mg of acetylsalicylic acid per well. The freeze-drying 127 
process was conducted using an automated lyophilization cycle on a Virtis Advantage XL 70 128 
freeze-dryer (Biopharma Process Systems, Winchester, UK). In the freezing step the samples 129 
were frozen to produce a required condition for low temperature drying (Nireesha, 2013). 130 
The sample was cooled from room temperature to 5 °C for 40 minutes, 5 °C to -10 °C for 40 131 
minutes, -10 °C to -55 °C for 120 minutes. An annealing process was integrated into the 132 
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freezing cycle to boost pore size distribution by increasing the temperature from -55 °C to -35 133 
°C (2 hours), cooled back to – 55 °C (3 hours) and maintained for 1 hour, at a pressure of 134 
200mTorr to assure uniformity. For the primary drying phase, the pressure was reduced to 50 135 
mTorr, and temperature was increased from -55 °C to -20 °C (8 hours) and further increased 136 
from -20 °C to -15 °C (10 hours). The secondary drying occurred at the same pressure as 137 
primary drying with temperature raised from -15 °C to 25 °C over 12 hours 30 minutes to 138 
remove the amount of water molecules that remained during primary drying (Okeke & 139 
Boateng, 2016). 140 
  141 
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Table 1. Polymeric solutions for preparing taste masked DL freeze-dried formulations in 100 ml aqueous ethanol (45 % v/v). The acetylsalicylic 142 
acid loading was such that each final wafer contained 75 mg of the drug. 143 
 144 












ratio   
 Total polymer excipient 
content in the solution  
(% w/v) 
DL MET:CAR Suc 1 1.87 0.63 0.00 3:1 7.5 1:1 2.50 
DL MET:CAR Asp 1 1.87 0.63 0.00 3:1 7.5 1:1 2.50 
DL MET:CAR Stev 1 1.87 0.63 0.00 3:1 7.5 1:1 2.50 
DL MET:CS Suc 2 3.00 0.00 1.00 1:3 7.5 1:1 4.00 
DL MET:CS Asp 2 3.00 0.00 1.00 1:3 7.5 1:1 4.00 
DL MET:CS Stev 2 3.00 0.00 1.00 1:3 7.5 1:1 4.00 
DL CAR:CS Suc 3 0.00 1.00 3.00 1:3 7.5 1:1 4.00 
DL CAR:CS Asp 3 0.00 1.00 3.00 1:3 7.5 1:1 4.00 
DL CAR:CS Stev 3 0.00 1.00 3.00 1:3 7.5 1:1 4.00 
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2.3 In vivo taste masking evaluation  145 
 Aspartame and sucralose were used at a sweetener to drug ratio of 1:1 to mask the 146 
bitter taste of acetylsalicylic acid in the optimized DL wafers, as outlined in Table 1.  Twelve 147 
healthy adult volunteers were recruited to take part in the taste masking assessments and were 148 
provided detailed written information about the study, and they subsequently gave signed 149 
informed consent with approval from the Ethics Committee of the University of Greenwich 150 
(12 December 2017). The volunteers were expected to make a suitable judgment on the taste 151 
of the wafers and give a written score. The wafers were placed on the tongue for 1 minute, 152 
the volunteers recorded their score and the sample was spat out and the mouth washed 153 
immediately with fresh drinking water. They subsequently responded to a questionnaire and 154 
scored each wafer from (1-10), using the following criteria: 1 (bitter), 5 (bland or no taste) 155 
and 10 (sweet). After collecting the results from the questionnaire, it was possible to identify 156 
which sweetener (sucralose or aspartame) was able to better mask the bitter taste of 157 
acetylsalicylic acid. As a control, commercially available chewable acetylsalicylic acid 158 
tablets (Bayer 81 mg), available in orange flavor was also judged by the volunteers in order 159 
to obtain a comparison of the formulated acetylsalicylic acid with a currently marketed 160 
chewable acetylsalicylic acid tablet.  161 
 162 
2.4 Physico-chemical characterization 163 
2.4.1 Texture analysis 164 
Texture analyzer (HD plus, Stable Micro System, Surrey, UK) fitted with a 5 kg load 165 
cell, was used to analyze the mechanical hardness (resistance to compression) and 166 
mucoadhesion properties of the taste masked DL wafers as previously reported (Boateng & 167 
Ayensu, 2014). Briefly, wafers (n = 3) were compressed in 3 or more places using a 2mm 168 
diameter probe and the resistance to compression determined for each formulation. To 169 
analyze the in vitro mucoadhesion behavior, each formulation was attached to an adhesive 170 
probe (35 mm diameter). Gelatin solution [6.67% (w/v)], was allowed to set to a gel, and 500 171 
µl of simulated saliva (SS) at pH 6.8 ± 0.1 spread over the surface of the set gelatin.  172 
The ex vivo mucoadhesion experiment was performed on taste masked DL wafers (n 173 
= 3) to estimate the effect of SS on their adhesion profiles on porcine buccal tissue. The 174 
samples were tested using the TA HD plus Texture Analyzer described above and the wafers 175 
were attached to an adhesive probe (75 mm diameter) with double sided adhesive tape. An 88 176 
mm diameter Petri dish containing buccal epithelium membrane of porcine tissue was used. 177 
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The wafers were positioned in contact with the epithelium for 60 seconds to provide optimal 178 
contact before being detached (Khan et al., 2015). 179 
 180 
2.4.2 Swelling capacity  181 
The swelling capacity of the taste masked DL wafers was determined by immersing 182 
each formulation into 5 ml of SS pH 6.8 ± 0.1 set at a temperature of 37 ± 0.1°C and 183 
weighing the swollen wafer at predetermined time intervals. The swelling capacity was 184 
determined for three replicates (n = 3) and calculated using equation 1.   185 
    (Equation 1) 186 
where; Wd = dry weight of wafers; Ws = weight of wafers after swelling  187 
 188 
The composition of various salts in 1L of SS was: 0.228 g of calcium chloride dihydrate, 189 
1.017 g of sodium chloride, 0.204 of sodium phosphate dibasic, 0.061 g of magnesium 190 
chloride hexahydrate, 0.603 g of potassium carbonate hemihydrate, 0.273 g of sodium 191 
phosphate monobasic monohydrate and 1.000 g of submaxillary mucin. The pH was adjusted 192 
to 6.8 ± 0.1 with phosphoric acid (Marques, et al., 2011).  193 
 194 
2.4.3 Scanning electron microscopy (SEM)  195 
The surface morphology of the gold coated taste masked DL wafers was analyzed 196 
using a Hitachi SU8030 (Hitachi High-Technologies, Krefeld, Germany at an accelerating 197 
voltage of 1 kV.  198 
 199 
2.4.4 Pore analysis  200 
The porosity of the wafers was measured using the solvent displacement method. 201 
Ethanol was used as it fills the pores and wets the wafers without hydrating them, compared 202 
to water which hydrates and eventually dissolves them. The taste masked DL wafers were 203 
weighed, completely immersed in 10 ml ethanol, covered, and left to stand for 2 hours for 204 
complete saturation. The saturated wafers were degassed to remove all air bubbles and the 205 
wafers subsequently removed very quickly from the solvent and immediately weighed. The 206 




     (Equation 2) 209 
 210 
where; Vp = pore volume 211 
            Vg = wafers geometrical volume 212 
             Wf = final weight of wafer 213 
             Wi = initial weight of wafer  214 
              ρe = ethanol density (0.789 g/cm
3)  215 
 216 
2.4.5 X-ray diffraction (XRD)  217 
X-ray diffractograms of taste masked DL wafers were obtained using a D8 Advantage 218 
X-ray diffractometer, by pressing the formulations before placing on the holder, mounting on 219 
the sample cell and analyzed in transmission mode at diffraction angle range of 5° to 50° 2θ, 220 
step size 0.04°, and scan speed of 0.4 s/step. 221 
 222 
2.4.6 Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR)  223 
ATR-FTIR spectra were obtained with a Perkin Elmer Spectrum instrument equipped 224 
with a diamond universal ATR unit. The taste masked DL wafers were placed on the ATR 225 
diamond crystal and force applied with a pressure clamp to allow suitable contact between 226 
the samples and the diamond crystal. Spectra were recorded at a resolution of 4 cm-1 within 227 
the range of 500-4000 cm-1 with subtraction of background spectra before plotting, to allow 228 
consistent absorbance of each sample. In addition, pure acetylsalicylic acid, aspartame, 229 
sucralose and physical mixtures of the drug with each sweetener, were analyzed by placing a 230 
small amount of the powder on the diamond crystal and the same process used for analyzing 231 
wafers was followed. 232 
 233 
2.4.7 In vitro drug release  234 
Drug dissolution of taste masked DL wafers was performed using a Franz-diffusion 235 
cell apparatus with its receptor compartment filled with 8 ml of SS pH 6.8 ± 0.1. The system 236 
was placed on a water bath at 37 °C and magnetically stirred (200 rpm). At predetermined 237 
time intervals, 0.5 ml aliquots (n = 3) of the SS were withdrawn, filtered through a 0.45 µm 238 
cellulose acetate membrane, and analyzed using HPLC by following the method previously 239 
reported (Farias & Boateng., 2018).  240 
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2.5 Permeation studies  241 
Permeation studies were undertaken for DL wafers using three different model buccal 242 
membranes; (i) in vitro EpiOralTM tissue culture membrane, (ii) ex vivo buccal tissue from pig 243 
cheek, (iii) in vitro artificial membrane barriers (PermeapadTM). 244 
 245 
2.5.1 EpiOralTM permeation studies 246 
 EpiOralTM assay medium (MatTek, Ashland MA, USA) was pre warmed to 37 ± 0.1 247 
°C for 30 minutes. Then, using a sterile technique, 0.3 mL/well of EpiOralTM assay medium 248 
were pipetted into 4 wells of a 24 well plate and labelled 1hour equilibrium. The remaining 249 
wells were labelled 30 minutes, 1, 2, 3 and 4 hours. The EpiOralTM samples were transferred 250 
into the 30 minute labelled well, treated with 0.5 mL donor solution (SS pH 6.8 ± 0.1) into 251 
which 15 mg of wafers was added with the mucoadhesive layer in contact with the apical 252 
surface of the EpiOralTM buccal tissue and returned to the incubator. After 30 minutes, the 253 
tissue was moved to the next time point until the total elapsed time (4 hours). 50 µL of the 254 
receiver fluid was collected at predetermined time intervals and transferred to a vial for 255 
HPLC analysis.  256 
 257 
2.5.2 Ex vivo permeation studies using pig cheek membrane 258 
The ex vivo permeation studies was performed using Franz diffusion cell. The Franz 259 
diffusion cell is a simple, reproducible test for measuring the in vitro drug release from 260 
formulations. The Franz cells consists of two primary chambers separated by a membrane of 261 
defined diameter, which determines the transportation area. The formulation is applied to the 262 
membrane via the top chamber (donor compartment). The bottom chamber (receptor 263 
compartment) contains the fluid from which samples are taken at regular intervals for 264 
analysis, which determines the amount of active drug per unit area that has permeated the 265 
membrane at each time point.  266 
Ex vivo permeation was performed by following previously reported method (Okeke 267 
& Boateng, 2016) (Ayensu, et al., 2012). Briefly, buccal tissues from the cheek of pigs were 268 
obtained from a local slaughterhouse (Tunbridge Wells, Kent, UK). After removal, the tissues 269 
were immediately transferred into cold Krebs buffer (pH 6.8 ± 0.1) modified with sodium 270 
carbonate, placed in sealed box filled with dry ice and quickly transported to the laboratory. 271 
The buccal mucosa, with part of the sub mucosa, was immediately separated from the fat and 272 
muscles using a sharp scalpel and the epithelium isolated from the underlying tissue. The 273 
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thickness of the sample was approximately 500 µm and the buccal mucosa was used within 2 274 
hours (Patel, et al., 2012). 275 
The prepared mucosal membrane was washed with SS at 37 °C and mounted between 276 
the donor and receiver compartments of a Franz-type diffusion cell, with the epithelial side 277 
facing the donor compartment to permit contact with the DL wafer (Attia, et al., 2004). 8 ml 278 
of SS at 37 ± 0.1 °C was placed in the receiver chamber with magnetic stirring at 250 rev/min 279 
to provide uniform mixing. After an equilibration period of 30 min, 0.5 ml of SS was placed 280 
in the donor compartment and 5 mg of the acetylsalicylic acid wafers was placed in the donor 281 
chamber with the mucoadhesion layer in contact with the epithelial surface. The 282 
compartments were held together by a cell clamp and sealed with parafilm to avoid 283 
evaporation. At predetermined time intervals, aliquots (1 ml) were withdrawn from the 284 
sampling port of the receiver compartment and replaced with the same amount of SS pH 6.8 285 
± 0.1 also at 37 ± 0.1 °C to maintain a constant volume for 2 hours. The sampled aliquots 286 
were analyzed using HPLC (n = 3) and the % cumulative permeation plotted against time 287 
(Khan, et al., 2015).  288 
 289 
2.5.3 PermeapadTM permeation studies  290 
  PermeapadTM barriers were placed between the donor and receiver chambers of the 291 
Franz-diffusion cells as described in previous studies (Bibi et al., 2015, 2016). The receiver 292 
compartment contained (8 mL) of SS at 37 ± 0.1 °C with magnetic stirring at 250 rev/min and 293 
the donor compartment was filled with (1.5 mL) of SS and 5 mg of DL wafers. The 294 
compartments were held together by a cell clamp and sealed with parafilm to avoid 295 
evaporation. At predetermined time intervals, aliquots (1 ml) were withdrawn from the 296 
sampling port of the receiver compartment and replaced with the same amount of SS pH 6.8 297 
± 0.1 to maintain a constant volume for 4 hours. The sampled aliquots were analyzed using 298 
HPLC (n = 3) and the % cumulative permeation plotted against time (Bibi, et al., 2015) (Bibi, 299 
et al., 2016). 300 
The permeation flux (J) across the EpiOralTM, pig cheek membrane and PermapadTM 301 
was determined using equation 3.  302 
       (Equation 3) 303 
where; J = steady state flux 304 
             dQ/dt = amount of drug permeated 305 
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             A = effective diffusion area 306 
 307 
2.6 Cell viability (MTT assay) 308 
 MTT assay on Vero cells was used to determine the cytotoxicity of pure MET, CAR, 309 
CS, acetylsalicylic acid, and the various formulated wafers. Vero cells (ATCC® CCL-81TM) 310 
are adherent cells derived from the kidney of the African Green monkey (Cercopithecus 311 
aethiops) and are one of the commonly used mammalian cell lines in cell biology, 312 
microbiology and molecular biology (Ammerman, et al., 2008). The Vero cells were obtained 313 
from the cell and tissue culture labs within the School of Science (Richardson Lab, 314 
University of Greenwich, Medway) and stored at -80 °C. The cells were used to seed a 315 
sterile, flat-bottomed 96 well tissue culture plate with Dulbecco’s modified Eagle’s medium 316 
(DMEM), fetal bovine serum (FBS) 10% (v/v), penicillin (100 units/mL), streptomycin (100 317 
µg/mL) and glutamine 0.292 mg/mL. Two cultures (treated and control) were kept under 318 
sterile conditions in a laminar hood and incubated at 37 °C in 5% (v/v) CO2 for 24 hours 319 
(Khan, et al., 2015). The controls only contained cells in growth media. The wafers and pure 320 
compounds were initially weighed (⁓ 175mg) and placed in flow cabinet under UV light for 321 
24 hours to sterilize. For the treated groups, the weighed sterilized samples were placed in 2.5 322 
mL of growth medium and left in the incubator for 24 hours, and the extract was filtered 323 
through 0.2 µm filter and collected into Eppendorf tubes. 324 
 The cells in culture medium were exposed to the collected sample extracts and 325 
incubated for 24 and 72 hours. For the former time period (24 hours), the cells were initially 326 
incubated for 20 hours, then 10 µL of MTT stock solution was added to each well and 327 
incubated for a further 4 hours.  For the latter incubation period (72 hours), the cells were 328 
initially exposed to new set of samples for 68 hours, 10 µL of the MTT stock solution was 329 
added to each well and the plate incubated for a further 4 hours, bringing the total incubation 330 
time to 72 hours. The contents of the plates (24 and 72 hours) were decanted and 100 µL of 331 
DMSO was added to each well, incubated at room temperature for 30 minutes and the 332 
absorbance read on a Multiscan EX Micro-plate photometer (Thermo Scientific, Essex, UK) 333 
at optical density (OD) of 540 nm. Data obtained was expressed as percentage cell viability 334 




2.7 Statistical analysis  337 
Statistical analysis was carried out to compare the results using two tailed student t-338 
test with 95% confidence interval (p-value < 0.05) as the minimum level of significance. All 339 
the experiments were carried out in triplicates with mean and standard deviation. 340 
 341 
3. Results and discussion  342 
Table 2 shows the porosity (%) of taste masked DL wafers relative to total polymer content in 343 
the original gels and polymer ratios. The results demonstrated that taste masked DL 344 
formulations containing sucralose were more porous than those with aspartame. However, 345 
there were no significant differences (p > 0.05) between the same formulation containing 346 
sucralose and aspartame. Formulations containing CS (DL CAR:CS Asp 3 and DL MET:CS 347 
Asp 2) showed lower porosity of 55 ± 5 % and 49 ± 4 % respectively, compared with the DL 348 
MET:CAR Suc 1 formulation, which showed a porosity  of 65 ± 3 %. The porosity results are 349 
confirmed by the SEM images in section 3.6, which showed that taste masked DL MET:CAR 350 
Suc 1 appeared more porous than the DL MET:CS Suc 2 and DL CAR:CS Suc 3 wafers, 351 
which were more compact. The porosity of the taste masked DL wafers was lower when the 352 
hardness results from section 3.3.1 were higher. This is due to the addition of the sweeteners 353 
which formed a compressed solid resulting in smaller pores and therefore, slowed down the 354 
penetration of solvent within the taste masked drug loaded wafer. This also affected swelling 355 
capacity as the DL MET:CAR taste masked formulations were able to swell more while the 356 
DL MET:CS and DL CAR:CS formulations which were less porous showed a lower swelling 357 
capacity in section 3.5, due to the compacted polymer structure, decreasing the water ingress 358 
(hydration) and subsequently % swelling capacity.  359 
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Table 2: Mechanical properties, porosity (%) and in vitro and ex vivo mucoadhesive profiles of taste masked DL wafers in simulated saliva (SS) 360 























DL MET:CAR Suc 1 26.16 ± 3.04 65 ± 3 0.21 ± 0.11 0.12 ± 0.10 0.96 ± 0.09 0.37 ± 0.15 0.42 ± 0.08 6.62 ± 1.54 
DL MET:CAR Asp 1 22.96 ± 4.45 63 ± 4 0.12 ± 0.05 0.05 ± 0.03 0.81 ± 0.12 - - - 
DL MET:CS Suc 2 20.00 ± 3.09 59 ± 2 0.12 ± 0.11 0.03 ± 0.03 0.83 ± 0.19 - - - 
DL MET:CS Asp 2 18.38 ± 1.02 49 ± 4 0.05 ± 0.04 0.02 ± 0.01 1.00 ± 0.14 0.25 ± 0.13 0.42 ± 0.12 5.14 ± 0.81 
DL CAR:CS Suc 3 18.79 ± 6.22 56 ± 2 0.17 ± 0.10 0.03 ± 0.00 1.18 ± 0.07 - - - 
DL CAR:CS Asp 3 10.35 ± 3.07 55 ± 5 0.03 ± 0.01 0.01 ± 0.00 1.09 ± 0.21 0.15 ± 0.10 0.93 ± 0.18 11.53 ± 0.81 
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Compared with the blank DL (non-taste masked) wafers (BDL), previously reported 363 
(Farias & Boateng, 2018), it can be observed that the BDL MET:CAR and BDL MET:CS 364 
showed higher porosity of 82 ± 12 and 75 ± 7 % respectively. This confirms both the 365 
hardness and SEM results which showed that the pores originally present before loading of 366 
sweeteners were largely filled with excess sweetener as well as recrystallized acetylsalicylic 367 
acid after freeze-drying. 368 
 369 
3.4 In vivo taste masking evaluation 370 
To improve patient adherence to medication, proven methods for reduction and 371 
inhibition of bitter taste have resulted in improved palatability of these formulations 372 
(Kleinert, et al., 1993). Taste is a function of sensation by the taste buds in the mouth and for 373 
formulations intended for geriatric, non-cooperative and bed ridden patients, the main 374 
challenge is to mask the taste of bitter drugs, to enhance patient acceptability and to ensure 375 
they will receive the optimal therapeutic dose of their medication (Momin, et al., 2012). 376 
Some of the methods employed in taste masking include coating of bitter drug particles with 377 
coating agents such as starch, polyvinyl pyrrolidone, gelatin, ethyl cellulose (Gowthamarajan, 378 
et al., 2004). Microencapsulation is a process of applying thin coating to small particles of 379 
solids, droplets of liquids and dispersions using coating agents such as gelatin and povidone. 380 
 Another commonly used method is to add sweeteners, as they impart a sweet taste 381 
that is highly preferred by geriatric and paediatric patients (Mennella, et al., 2011) and was 382 
the method of choice in this study. Taste-masked formulations can be challenging to develop, 383 
and the best method is often dictated by the physicochemical properties and taste profile of 384 
the drug (Vesey, 2018). Taste masking by amino acids, sweeteners and flavours is the most 385 
simple and oldest technique for improving taste characteristic of active ingredients within 386 
formulations. The sweeteners and flavours overcome the unpleasant taste by occupying the 387 
taste buds and therefore preventing direct sensation of the bitter taste of the drug of interest, 388 
long enough to allow effective therapeutic dosing (Karolewicz, 2016). The aim of the taste 389 
masking study was to solicit judgement of human volunteers about the taste of the optimized 390 
DL wafers (CAR:CS, MET:CS and MET:CAR) loaded with sucralose or aspartame, to help 391 
in the selection of the most suitable formulations for the target (geriatric) patient group. The 392 
participants were required to choose a number between 1 and 10, in which 1 was (bitter) 5 393 
(bland or no taste) and 10 (sweet) and scores for each formulation by the 12 volunteers are 394 
summarised in Table 3.   395 
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Table 3. Results of in vivo taste masking study showing the selected optimized samples 396 
and the scores per taste category (i.e. bitter, bland, and sweet) for each formulation as 397 
judged by the volunteers. Scores from 5 to 10 (bland – sweet) were considered as having 398 
masked the bitter taste.  399 
  Number of volunteers giving a particular score 
 Scores 1 2 3 4 5 6 7 8 9 10 
Sample Formulations Bitter Bland Sweet 
A DL MET: CAR 
Suc 1  
  1  1 2 3 4 1  
E DL CAR: CS 
Asp 3 
1 2 2 1 2 3    1 
F DL MET: CS 
Asp 2 







  1  4 3 3 1   
 400 
The in vivo taste masking evaluation were performed on 3 optimized formulations and 401 
showed that sucralose and aspartame were able to mask the bitter taste of acetylsalicylic acid 402 
in the DL MET:CAR Suc1, DL CAR:CS Asp 3 and DL MET:CS Asp 2, respectively. 403 
Overall, the formulations containing DL MET:CAR and MET:CS showed more palatability 404 
and acceptance because according to Amelian and Winnicka, MET also possesses appropriate 405 
properties to be used for effective taste masking (Amelian & Winnicka, 2017). At the 406 
molecular level, the drug-polymer complex with aspartame or sucralose exhibited significant 407 
taste-masking, as confirmed in the taste assessment by volunteers. As a result of the in vivo 408 
taste masking evaluation, further characterizations were performed on the DL MET:CAR 409 
Suc1, DL CAR:CS Asp 3 and DL MET:CS Asp 2. The volunteers also judged a 410 
commercially available chewable acetylsalicylic acid with orange flavour to compare with 411 
the results for the formulated wafers. Though the commercially available chewable 412 
acetylsalicylic acid was largely accepted, some volunteers judged it as bitter or bland, and 413 




3.5 Swelling capacity  416 
The swelling capacity of DL MET:CAR Suc 1, DL CAR:CS Asp 2 and DL MET:CS 417 
Asp 3 are shown in Figure 1. The % swelling capacity for (DL MET:CAR 3:1 Suc) was 418 
observed to be 283 ± 47 %. The high rate of swelling is related to the total percentage 419 
polymer content (by weight), as they were prepared from 2.5% w/v gels while the other taste 420 
masked formulations, were prepared from 4.0% w/v gels with the latter being more dense due 421 
to the higher total polymer content after freeze-drying. DL MET:CS Asp 2 wafers showed a 422 
swelling capacity of 185 ± 33 %. The results showed that MET in the formulations made the 423 
wafers more stable, thus they had longer duration of swelling of about 30 to 70 minutes, 424 
before disintegrating, compared to the DL CAR: CS Asp 3 formulations. This is because 425 
MET acts as a stabilizer for the wafers (Shin Etsu Chemical, 2005). DL CAR:CS Asp 2 wafer 426 
was able to maintain its structural integrity for 10 minutes, after which it disintegrated 427 
because of excessive absorption of water molecules. Compared to our previously reported 428 
study (Farias & Boateng, 2018) of DL formulations without any sweeteners, the taste masked 429 
DL wafers showed lower swelling capacity. This could be due to the increased hardness and 430 
brittleness of the taste masked DL wafers because of the compact and denser solid matrix that 431 
resulted in wafers with smaller pores and therefore, less capacity for water ingress (Kianfar, 432 
et al., 2014).   433 
 434 
Figure 1. Swelling profiles of taste masked acetylsalicylic acid loaded wafers (DL MET:CAR 435 
Suc 1, DL CAR:CS Asp 3 and DL MET:CS Asp 2) in SS. It was determined for three 436 
replicates (mean ± SD, n = 3) and calculated using equation 1.  437 
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The maximum swelling capacity (%) of the taste masked DL wafers occurred within 2 438 
minutes compared to the DL wafers without sweeteners as previously reported (Farias & 439 
Boateng, 2018). The reason for the rapid water ingress in the former is because of the high 440 
water solubility of both sweeteners. When compared with results in PBS (Farias & Boateng, 441 
2018), the swelling capacity values were lower in SS which can be attributed to the difference 442 
in ionic strength of the media which plays an important role in the swelling profile of porous 443 
formulations such as wafers (Peh & Wong, 1999).  444 
 445 
3.6 Scanning electron microscopy (SEM) 446 
Figure 2 (a) and (b) shows the surface morphology of the sweeteners’ (aspartame and 447 
sucralose) crystals. The morphology of acetylsalicylic acid crystals have been previously 448 
reported (Farias & Boateng., 2018). It was observed that the aspartame and sucralose crystals 449 
were similar as they are mainly composed of maltodextrin and the particles seem to be fused 450 
with each other, thus forming larger clusters with no uniform size or shape (Singh, et al., 451 
1993). Figure 2 (c to e) shows the surface morphology of representative taste masked DL 452 





Figure 2.  SEM images showing surface morphology of (A) aspartame, (B) sucralose, and 456 
internal porous structure of (C) BDL MET:CAR (DL only wafer) (D) DL MET:CAR Suc 1, 457 
(E) DL CAR:CS Asp  3 and (F) DL MET:CS Asp 2.  458 
 459 
The taste masked DL wafers showed a very compact matrix structure with crystals of 460 
excess acetylsalicylic acid and maltodextrin distributed over their surfaces, which is a major 461 
reason for the high hardness values described in section 3.1 above. The small pores in these 462 
taste masked DL formulations is attributed to the thicker walls formed due to polymer- drug 463 
interaction (Farias & Boateng, 2018) and addition of sweetener. The SEM images confirm 464 
the swelling capacity results in section 3.5, with the DL MET:CAR Suc 1 able to swell more 465 
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due to being more porous, and thus exhibiting faster rate of water ingress and hydration, 466 
compared to DL MET:CAR Asp 2 and DL CAR:CS Asp 3. 467 
 468 
3.7 X-ray diffraction (XRD) 469 
The transmission diffractograms of acetylsalicylic acid, sucralose, aspartame, and 470 
representative taste masked DL formulations (DL MET:CAR Suc 1, DL MET:CS Asp 2 and 471 
DL CAR:CS Asp 3) are shown in Figure 3. The results confirm the amorphous nature of the 472 
sweeteners (sucralose and aspartame) demonstrated by the broad peak at 2θ of 15° and 25°. 473 
Acetylsalicylic acid showed its crystalline nature with the presence of sharp peaks at 2θ of 474 
15°, 20°, 23° and 27°. The crystalline peaks from acetylsalicylic acid can be observed at the 475 
same 2θ positions of 15°, 20°, 23° and 27° in the diffractograms of the taste masked DL 476 
formulations (DL MET:CAR Suc 1, DL MET:CS Asp 2 and DL CAR:CS Asp 3) suggesting 477 
that the addition of sweeteners did not change the crystallinity of the acetylsalicylic acid 478 







Figure 3.  XRD-transmission diffractograms of acetylsalicylic acid, sucralose, aspartame and taste masked DL formulations (DL MET:CAR Suc 484 
1, DL MET:CS Asp 2 and DL CAR:CS Asp 3. 485 
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3.8 Attenuated total reflectance – Fourier transform infrared (ATR-FTIR) 486 
Figure 4 (a) shows the ATR-FTIR spectra of pure sucralose, aspartame, 487 
acetylsalicylic acid and physical mixtures of acetylsalicylic acid with aspartame and 488 
acetylsalicylic acid with sucralose. Sucralose is manufactured by the selective chlorination of 489 
sucrose, in which three of sucrose’s hydroxyl groups are substituted with chlorine atoms. 490 
Dextrose and maltodextrin are used as bulking agents and are the major components of the 491 
sweetener. The IR spectrum contains a broad band near 3258 cm-1 due to the hydrogen 492 
bonded hydroxyl (O-H) groups in the structure. There are C-H symmetric and asymmetric 493 
stretching bands between 2800 and 3000 cm-1 and a series of bands between 1200 and 650 494 
cm-1 which are the result of vibration of the C-O, C-C and C-O-H groups of the sugar. The 495 
spectrum of aspartame was similar to that of sucralose as the major components of both 496 
sweeteners is maltodextrin.  497 
498 
 499 
Figure 4a. ATR-FTIR spectra of pure acetylsalicylic acid, sucralose, aspartame, and physical 500 




The IR spectra of acetylsalicylic acid which has three functional groups, a benzene 503 
ring (aromatic group), a carboxylic acid (COOH) group and an ester (R-C=O-O-R) group is 504 
also shown in Figure 4a. The broad and wide peak from 2500 to 3300 cm-1 represents the 505 
carboxylic acid (COOH) part of the molecule. The aromatic functional group is represented 506 
by the sharp peak for the C-H stretch around 1710-1780 cm-1, a medium peak around 1500-507 
1700 cm-1 and a carbonyl C=O group stretch around 1710-1780 cm-1. The ester group is 508 
represented by a C=O stretch at 1735-1750 cm-1. 509 
Figure 4 (b) shows the ATR-FTIR of taste masked DL formulations (DL MET:CAR 510 
Suc 1, DL MET:CS 1:3 Asp 2 and DL CAR:CS Suc 3). It can be observed that there was 511 
interaction of acetylsalicylic acid with the polymers as well as with the sweeteners by the 512 
2500 cm-1 to 3300 cm-1 band representing the COOH group. This interaction is shown by the 513 
shifting of the peaks to a high wavenumber and the reduced peak intensity between 1710 – 514 
1780 cm-1 (aromatic group) for acetylsalicylic acid.  The bands at 1223 cm-1 and 843 cm-1 515 
were attributed to O-S-O symmetric vibration and the band at 925 cm-1 demonstrated the 516 
existence of C-O-C of the 3,-anhydro-D-galactose for CAR. The bands around 3389, 1036 517 
cm-1 were related to O-H and C-O stretch. 518 
 519 
Figure 4b. ATR-FTIR spectra of taste masked DL formulations (DL MET:CAR Suc 1, DL 520 
MET:CS Asp 2 and DL CAR:CS Asp 3).  521 
25 
 
The intense band at 1625 cm-1 was related to the deformation of hydrogen bond in 522 
water and described as water deformation band (Farias & Boateng, 2018). The interaction is 523 
also confirmed by the presence of C-H symmetric and asymmetric stretching bands between 524 
2800 and 3000 cm -1 and a series of bands between 1200 and 650 cm -1 which is a result of 525 
vibration of the C-O, C-C and C-O-H groups of the sugars (dextrose and maltodextrin) 526 
present in the sweeteners within the taste masked DL formulations.  527 
 528 
3.9 In vitro drug release  529 
The drug dissolution study was carried on samples that were optimized from the in-530 
vivo taste masking evaluation using SS at pH 6.8 ± 0.1 as observed in Figure 5.  531 
 532 
Figure 5. Drug dissolution profiles of selected optimized taste masked DL formulations (DL 533 
MET:CAR Suc 1, DL MET:CS Asp 2 and DL CAR:CS Asp 3) in SS at pH 6.8 ± 0.1 (mean ± 534 
SD, n = 3). 535 
 536 
The mean percent released was 63.9 %, 89.1 % and 81.1 % for DL MET:CAR Suc 1, 537 
DL CAR:CS Asp 3 and DL MET:CS Asp 2 respectively, in the first 20 minutes. The DL 538 
MET:CAR Suc 1 wafers achieved maximum release of 99.1 % in 60 minutes, while the DL 539 
CAR:CS Asp 3 and DL MET:CS Asp 2 wafers achieved maximum release of 99.5 and 99.3 540 
% respectively in 40 minutes. DL MET:CAR Suc wafers were able to release the drug for a 541 
longer period. This is due to the MET in the formulations which helps to increase the 542 
viscosity and density of the formulations, thus slowing drug diffusion and release. When 543 
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comparing the taste masked DL formulations with the BDL formulations with no sweeteners 544 
from previous studies (Farias & Boateng, 2018), it can be observed that the % release in SS 545 
increased with the addition of sweetener. For example, DL MET:CAR Suc 1 had a percent 546 
release of 63.9 % at 20 minutes and the respective BDL formulation had a percent release of 547 
14.5 %. Addition of sweetener in the formulation enhanced the rate of drug release from the 548 
polymeric systems and this is because sucralose and aspartame are highly water soluble 549 
materials which allowed a faster ingress of dissolution medium into the wafers and 550 
subsequent rapid hydration, swelling and drug diffusion from the swollen matrix and its 551 
subsequent erosion.    552 
The observed drug release period appears to be a relatively long time for buccal 553 
absorption. However, once the wafer becomes fully hydrated, it is expected to form a flowing 554 
gel, which will then be mixed with saliva and the patient can unconsciously swallow more 555 
readily. This is an important advantage for geriatric patients with dysphagia, who will 556 
typically struggle to swallow solid or even semi solid formulations. Since acetyl salicylic acid 557 
is stable in the gastric acid, eventual swallowing is not expected to be a limitation. 558 
 559 
3.10 Permeation studies  560 
3.10.1 EpiOralTM permeation studies 561 
EpioralTM has been previously used in the permeation studies of lyophilized thiolated 562 
chitosan xerogels for buccal delivery of insulin (Boateng, et al., 2014). In their study the 563 
permeation parameters of insulin for the optimized drug loaded chitosan xerogels through the 564 
EpioralTM was determined. Another study which used the EpioralTM was reported by Giovino 565 
and co-workers, who developed an integrated buccal delivery system combining chitosan 566 
films impregnated with insulin loaded PEG-b-PLA nanoparticles (Concetta, et al., 2013). 567 
EpioralTM was also used by Brian Keyser and colleagues, for the development of 3D human 568 
oral tissue model for oral permeation of smokeless moist snuff (Keyser, et al., 2018). The 569 
cumulative permeation curves of the optimised taste masked DL wafers using EpiOralTM 570 
buccal tissue are shown in Figure 6. The permeation flux (J) of acetylsalicylic acid released 571 





Figure 6. Cumulative permeation curve of optimized DL wafers using EpiOralTM buccal 575 
tissue (n = 3, ± SD). 576 
 577 
The highest cumulative permeation within 4 hours and permeation flux (J) was 578 
observed for BDL MET: CAR wafer with the maximum cumulative permeation of 1440 ± 579 
1.0 µg/cm2 and permeation flux (J) of 360 ± 0.3 µg/cm2/h. The BDL MET: CS wafers 580 
demonstrated the lowest cumulative permeation and permeation flux within 4 hours, with a 581 
maximum cumulative permeation of 90 ± 2.7 µg/cm2  and permeation flux (J) of 22.4 ± 6.7 582 
µg/cm2/hr which were significantly different (p < 0.05) from the other two formulations. Due 583 
to the high cost of EpiOralTM tissue and associated budgetary constraints for the current 584 
research, it was not possible to test permeation for the corresponding taste masked 585 
formulations, therefore, both sets of optimized formulations (taste masked and non-taste 586 
masked wafers) were further tested for permeation using cheaper ex vivo porcine model and 587 





Table 4. Permeation flux (J) for optimized DL wafers from porcine tissue, PermeapadTM and 591 
EpiOralTM buccal tissue. 592 
 Formulation Flux (J) (µg/cm2/h) (mean 
± SD, n = 3) 
 
EpiOralTM 
BDL MET: CAR 360.0 ± 0.3 
BDL MET: CS 22.4 ± 6.7 
BDL CAR: CS 129.3 ± 7.5 
 
Porcine tissue 
DL MET:CAR Suc 1 19.5 ± 1.4 
DL CAR:CS Asp 3 7.9± 0.7 
DL MET:CS Asp 2 5.9 ± 1.9 
 
PermeapadTM 
DL MET:CAR Suc 1 14.7 ± 1.5 
DL CAR:CS Asp 3 18.0 ± 5.1 
DL MET:CS Asp 2 9.1 ± 0.5 
 593 
3.10.2 Ex-vivo permeation studies 594 
The cumulative permeation curve of the optimized taste masked DL wafers using 595 
porcine buccal tissue are shown in Figure 7 and the permeation flux (J) values are shown in 596 
Table 4. The taste masked DL wafers in general showed a significantly (p < 0.05) lower 597 
cumulative permeation than the corresponding BDL (non-taste masked) formulations. The 598 
highest cumulative permeation and permeation flux (J) was shown for DL MET:CAR Suc 1 599 
with the maximum cumulative permeation of 78.0 ± 5.5 µg/cm2 within 4 hours and 600 
permeation flux (J) of 19.5 ± 1.4 µg/cm2/h while the lowest cumulative permeation and 601 
permeation flux (J) was shown for optimized taste masked DL MET:CS Asp 2 with the 602 
maximum cumulative permeation of 24 ± 7 µg/cm2 within 4 hours and permeation flux (J) of 603 





Figure 7. Cumulative permeation curve of optimized taste masked DL wafers using porcine 607 
buccal tissue (n = 3, ± SD). 608 
 609 
3.10.3 PermeapadTM permeation studies  610 
The cumulative permeation curves of the optimized taste masked DL wafers using 611 
PermeapadTM are shown in Figure 8 and the permeation flux (J) of acetylsalicylic acid are 612 
shown in Table 4. The highest cumulative permeation within 4 hours and the permeation flux 613 
(J) was observed for DL CAR:CS Asp 2 wafers with the maximum cumulative permeation of 614 
59 ± 6 µg/cm2 and permeation flux (J) 14.7 ± 1.5 µg/cm2/h for DL MET:CAR Suc 1. 615 
Optimized DL MET:CS Asp 2 wafers demonstrated lowest cumulative permeation within 4 616 
hours and permeation flux (J), with a maximum cumulative permeation of 36 ± 2 µg/cm2 and 617 






Figure 8. Cumulative permeation curve of optimized taste masked DL wafers using 622 
PermeapadTM artificial barrier (n = 3, ± SD). 623 
 624 
Generally, the rates of hydration, swelling, release of acetylsalicylic acid from the 625 
formulations and mucoadhesion played a role on the permeation flux via the three different 626 
permeation models employed (EpiOralTM, porcine buccal tissue and PermeapadTM artificial 627 
buccal membrane). EpiOralTM buccal tissue demonstrated a higher flux than porcine buccal 628 
tissues which can be attributed to fatty tissues beneath the porcine buccal mucosa tissue. On 629 
the other hand, PermeapadTM artificial barrier demonstrated a lower flux than porcine and 630 
EpiOralTM buccal tissues. Though PermeapadTM demonstrated lower cumulative permeation 631 
than the other buccal permeation models tested, the results indicated that PermeapadTM is well 632 
suited as a cheap alternative for fast and reliable preliminary prediction of passive drug 633 
permeability (Bibi, et al., 2015). Moreover, the investigated biomimetic barrier has been 634 
proven to maintain its functionality over time and in different pH environments (di Cagno, et 635 
al., 2015), making it a useful addition to the in vitro permeation testing tool kit. The reason 636 
for the low permeation and permeation flux (J) in the taste masked DL formulations is 637 
confirmed by the SEM results in section 3.6, which showed that the taste masked DL wafers 638 
were more compacted with crystals of excess acetylsalicylic acid and maltodextrin distributed 639 
over their surfaces, blocking the wafer pores. 640 
.  641 
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3.11 MTT assay 642 
 There are many factors involved in determining the successful and safe application of 643 
polymers as drug carriers in humans, with toxicity being an important factor (Khan, et al., 644 
2016). Tissue viability was assessed using 3-[4,5-dimethylthiazol-2-ul]-2,5 diphenyl 645 
tetrazolium bromide (MTT) cytotoxicity testing for pure polymers, acetylsalicylic acid, 646 
optimized BLK and DL formulations previously reported in (Farias & Boateng, 2018) and the 647 
taste masked acetylsalicylic acid loaded formulations. This is a reduction assay where yellow 648 
MTT is reduced to purple formazan primarily by the action of enzymes which are located 649 
inside the mitochondria of the viable cells (Koschier, et al., 2011). Figure 9 shows the 650 
respective cell viability data for the samples described when exposed to Vero cells as 651 
measured by MTT assay after 24 hours. Triton-X-100 (positive control) killed 90% of cells 652 
compared with untreated cells (negative control) after 24 hours of exposure. Data for 72 653 
hours incubation are not shown as they were similar to that after 24 hours, which is a more 654 
ideal exposure time for buccal delivery. 655 
 656 
 657 
Figure 9. MTT assay results, showing cell viability of pure polymers and pure drug, BDL 658 
loaded formulations (non-taste masked), their respective blank (no acetylsalicylic acid 659 
loaded) wafers, taste masked DL wafers, Triton-X-100 and untreated cells (mean ± SD, n = 660 




The results show a clear profile of the cytotoxicity of the pure materials, and the various 663 
formulations on adherent mammalian cells with greater than 70% cell viability in all cases. 664 
This confirms that the pure polymers, pure acetylsalicylic acid and the drug released from the 665 
taste masked DL wafers were non-toxic and can be employed for geriatric drug delivery 666 
(Moritz, et al., 2014). This study confirms that acetylsalicylic acid poses no physical threats 667 
to endothelial cells when used for potential buccal application in geriatric patients compared 668 
with the known toxic Triton-X-100.  669 
In addition to MTT cell viability testing, mucosal irritation caused by formulations 670 
meant for local application to the buccal mucosa is important. However, the wafers were 671 
designed and formulated using well known and FDA approved mucoadhesive GRAS 672 
(generally regarded as safe) polymers of high viscosity with greater flexibility and optimum 673 
chain length to avoid mucosal irritation. Among the various mucoadhesive drug delivery 674 
systems, buccal wafers and films are better than oral gels due to relatively longer residence 675 
time, more flexibility to cover the buccal mucosa and better comfort (Semalty, et al., 2010). 676 
Furthermore, the neutral environment of the mouth allows for administration of acidic drugs 677 
such as acetylsalicylic acid (Ribeiro Costa, et al., 2019). The salivary pH varies from 5.5 to 678 
7.0 and the wafers produced would therefore not be expected to produce any local irritation to 679 
the mucosal surface upon application (Kassem, et al., 2015). However, this will require 680 
further investigation in the future in the form of mucosal irritation test, to confirm it 681 
definitively. 682 
 683 
4. Conclusions  684 
 The functional properties of taste masked DL wafers for geriatric delivery, have been 685 
characterized. Wafers comprising sucralose and aspartame showed higher hardness compared 686 
to their corresponding non-taste masked wafers which was reflected in the SEM, swelling 687 
capacity and porosity results. However, adding the sweeteners increased the rate of release 688 
compared to the BDL formulations. Both sucralose and aspartame showed similar effect in 689 
masking the bitter taste of acetylsalicylic acid while MET:CAR and MET:CS wafers showed 690 
more palatability and acceptance because of MET’s known taste masking properties. The 691 
wafers showed enough drug permeability after release of acetylsalicylic acid through 692 
EpiOralTM, porcine buccal tissues and artificial PermeapadTM membrane, which is expected 693 
to ensure therapeutic bioavailability and therefore a potentially useful alternative to oral 694 
tablets. MTT assay showed that all the wafers were safe for continuous attachment in the 695 
cheek region and therefore suitable for geriatric patients. Taste masked DL formulations (DL 696 
33 
 
MET:CAR Suc 1, DL CAR:CS Asp 3 and DL MET:CS Asp 2) are very promising systems 697 
for the delivery of low dose acetylsalicylic acid to geriatric patients with dysphagia.  698 
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